Spyre Therapeutics, Inc.
SYRE
Kedudukan dalam Saham
#2589
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$80.03
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$7.39B
Perubahan (1 hari)
-0.09%
Perubahan (1 tahun)
256.14%
Negara
US
Perdagangan Spyre Therapeutics, Inc. (SYRE)
Kategori
Healthcare
Margin Operasi untuk Spyre Therapeutics, Inc. (SYRE)
Margin Operasi pada October 2026 TTM: -222.49%
Menurut laporan kewangan dan harga saham terkini Spyre Therapeutics, Inc., margin operasi semasa (TTM) ialah -222.49%. Pada akhir 2023, margin operasi syarikat ialah -27,347.97%.
Sejarah Margin Operasi untuk Spyre Therapeutics, Inc. dari 2013 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Ubah |
|---|---|---|
| 2026 (TTM) | -222.49% | -100.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -27,347.97% | 651.27% |
| 2022 | -3,640.23% | 939.09% |
| 2021 | -350.33% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -1,169.32% | 119.91% |
| 2017 | -531.72% | 12.33% |
| 2016 | -473.34% | 154.55% |
| 2015 | -185.95% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Margin Operasi untuk syarikat serupa atau pesaing
| Syarikat | Margin Operasi | Perbezaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -100.17% |
US
|
|
| -149.01% | -99.33% |
US
|
|
| 25.57% | -100.11% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.13% |
NL
|
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.